Dihydroartemisinin and sorafenib work synergistically to increase the levels of ROS and decrease the levels of proteins, including GPX4, thus, inducing ferroptosis in hepatoma cells [124]. The gene discussed is GPX4; the disease is hepatocellular carcinoma.